Darvias (darinaparsin) () vs Brukinsa (zanubrutinib)

Darvias (darinaparsin) is a novel organic arsenic compound with potential antineoplastic activity, primarily investigated for the treatment of various types of cancer, including hematologic malignancies and solid tumors. Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor used specifically for the treatment of mantle cell lymphoma (MCL) and other B-cell malignancies. When deciding between Darvias and Brukinsa, it is crucial to consider the specific type of cancer being treated, as Brukinsa is specifically approved for certain B-cell cancers, while Darvias may have a broader investigational use but may not be approved for the specific condition in question.

Difference between Darvias (darinaparsin) and Brukinsa

Metric	Darvias (darinaparsin)	Brukinsa (zanubrutinib)
Generic name	darinaparsin	zanubrutinib
Indications	Currently in clinical trials for various types of cancer, including lymphoma and solid tumors.	Approved for the treatment of mantle cell lymphoma (MCL) in patients who have received at least one prior therapy, Waldenström's macroglobulinemia, and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Mechanism of action	Induces apoptosis through mitochondrial pathways and has anti-tumor activity.	Bruton's tyrosine kinase (BTK) inhibitor that prevents the growth and spread of cancer cells.
Brand names	Darvias is not yet approved, so it does not have a brand name.	Brukinsa
Administrative route	Intravenous	Oral
Side effects	Nausea, vomiting, fatigue, and elevated liver enzymes, among others.	Neutropenia, thrombocytopenia, anemia, diarrhea, bruising, cough, and rash, among others.
Contraindications	Not yet fully established due to ongoing clinical trials.	Hypersensitivity to zanubrutinib, active bleeding, infection, and concurrent use of strong CYP3A inhibitors or inducers.
Drug class	Organic arsenic compound	BTK inhibitor
Manufacturer	ZIOPHARM Oncology	BeiGene

Efficacy

Efficacy of Darvias (Darinaparsin) in Lymphoma Treatment

Darinaparsin, known by the brand name Darvias, is an organic arsenic compound with potential antineoplastic activity. Although not primarily indicated for lymphoma, studies have shown that darinaparsin can induce apoptosis in malignant cells, including those from patients with lymphoma. Preclinical studies have suggested that darinaparsin may be effective against various types of lymphoma, including Hodgkin's lymphoma and non-Hodgkin lymphoma. However, it is important to note that the use of darinaparsin in lymphoma treatment is considered off-label, and more clinical trials are needed to fully establish its efficacy and safety profile for this particular indication.

Efficacy of Brukinsa (Zanubrutinib) in Lymphoma Treatment

Zanubrutinib, sold under the brand name Brukinsa, is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in treating lymphoma, particularly mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia, which is a rare type of non-Hodgkin lymphoma. Clinical trials have demonstrated that zanubrutinib can achieve a high rate of response in patients with MCL, with a significant proportion of patients achieving complete remission. The drug has been granted accelerated approval by the FDA for the treatment of mantle cell lymphoma in patients who have received at least one prior therapy.

Furthermore, zanubrutinib has been studied in other B-cell malignancies, including marginal zone lymphoma (MZL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In these studies, zanubrutinib has shown promising results, with a favorable safety profile and high overall response rates. The efficacy of zanubrutinib in these lymphomas supports its role as a valuable therapeutic option for patients with B-cell malignancies.

It is important for patients and healthcare providers to discuss the potential benefits and risks of using these medications for lymphoma treatment. While Darvias (darinaparsin) may be considered for off-label use in certain cases, Brukinsa (zanubrutinib) has been specifically approved for certain types of lymphoma and continues to be evaluated in clinical trials for its efficacy in other lymphoma subtypes. As with any medication, the decision to use these drugs should be made based on a comprehensive evaluation of the individual patient's condition and the most current clinical evidence available.

Regulatory Agency Approvals

Darvias (darinaparsin)

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Brukinsa

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Darvias (darinaparsin) or Brukinsa today

If Darvias (darinaparsin) or Brukinsa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Darvias (darinaparsin)

Buy Brukinsa

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: